 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Simple sentinel lymph node resection is expected to replace pelvic lymph node dissection for early cervical cancer!

Eur J Cancer: Simple sentinel lymph node resection is expected to replace pelvic lymph node dissection for early cervical cancer!

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

pancreatic cancer detection

unmc cancer center

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The most important prognostic factor for early cervical cancer is lymph node status.

Sentinel lymph node (SN) identification is considered to be an effective method for assessing lymphatic metastasis, which can increase the detection rate of metastatic disease

Recently, a study published in the European Journal of Cancer " Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2) " evaluated the omission of pelvic lymph node dissection and the prognosis of early cervical cancer Relevance .

Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2) is omitted and pelvic lymphadenectomy early cervical cancer Prognosis

This is an open study.

Metastatic SN cases in both groups

A total of 206 patients were recruited and randomly divided into SN group (105 cases) and SN+PLND group (101 cases).

Lymphatic morbidity within 6 months after surgery

The incidence of lymphatic vessels in the SN group (31.

Three-year recurrence-free survival rate

At 6 months after surgery, the difference in the incidence of lymph nodes between the two groups decreased over time.

The 3-year recurrence-free survival rates of the SN group and SN+PLND group were 92.

In early cervical cancer, compared with SN+PLND, simple SN resection (that is, omission of pelvic lymph node dissection) is associated with a decrease in the incidence of early lymphatic vessels, and does not significantly affect the patient’s recurrence-free survival rate.

Original source:

Mathevet Patrice,Lécuru Fabrice,Uzan Catherine et al.

org/10.
1016/j.
ejca.
2021.
02.
009" target="_blank" rel="noopener">Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2) in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.